statistiche ricercatore

Continente	#
NA - Nord America	1.090
EU - Europa	915
AS - Asia	532
SA - Sud America	86
AF - Africa	19
OC - Oceania	2
Continente sconosciuto - Info sul continente non disponibili	1
Totale	2.645

Nazione	#
US - Stati Uniti d'America	1.061
RU - Federazione Russa	293
GB - Regno Unito	221
CN - Cina	186
SG - Singapore	182
IT - Italia	100
DE - Germania	78
BR - Brasile	64
SE - Svezia	50
VN - Vietnam	46
HK - Hong Kong	44
FI - Finlandia	42
IE - Irlanda	39
FR - Francia	34
CA - Canada	18
KR - Corea	17
BE - Belgio	13
JP - Giappone	12
NL - Olanda	12
IN - India	10
ES - Italia	9
TR - Turchia	9
UA - Ucraina	9
BD - Bangladesh	7
MX - Messico	7
AR - Argentina	6
ZA - Sudafrica	6
ID - Indonesia	5
VE - Venezuela	5
EC - Ecuador	4
NG - Nigeria	4
AT - Austria	3
CO - Colombia	3
EG - Egitto	3
PK - Pakistan	3
PL - Polonia	3
PY - Paraguay	3
RO - Romania	3
AU - Australia	2
ET - Etiopia	2
IQ - Iraq	2
PT - Portogallo	2
SA - Arabia Saudita	2
AE - Emirati Arabi Uniti	1
AL - Albania	1
AZ - Azerbaigian	1
BF - Burkina Faso	1
BG - Bulgaria	1
CW - ???statistics.table.value.countryCode.CW???	1
DO - Repubblica Dominicana	1
GA - Gabon	1
IR - Iran	1
JM - Giamaica	1
KG - Kirghizistan	1
LT - Lituania	1
MA - Marocco	1
MY - Malesia	1
PA - Panama	1
PE - Perù	1
PH - Filippine	1
SI - Slovenia	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
TW - Taiwan	1
Totale	2.645

Nome	#
Interferon-alpha-engineered Multipotent Mesenchymal Stromal Cells for the treatment of myeloma	311
IFN-gamma- Mediated Upmodulation of MHC Class I Expression Activates Tumor-Specific Immune Response in a Mouse Model of Prostate Cancer	295
IFNalpha-producing bone marrow mesenchymal stem cells (BM-MSCs) contrast tumor growth in a mouse myeloma model.	294
IFN-gamma- Mediated Upmodulation of MHC Class I Expression Associated to a B7-1-Expressing Tumor Cell Vaccine Activates Tumor-Specific Immune Response in a Mouse Model of Prostate Cancer.	282
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma	260
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer	230
Efficacy assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model	228
Homing and Efficacy Assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmocytoma model	226
Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens	212
Interferon-alpha-engineered Multipotent Mesenchymal Stromal Cells for the treatment of myeloma	186
CONTROL OF CANCER IMMUNOEDITING BY AUTOLOGOUS CELLULAR VACCINE AND EFFICACY ASSESSMENT OF IFN-alpha-ENGINEERED MESENCHYMAL STROMAL CELLS (MSCs) IN A MOUSE PLASMACYTOMA MODEL	158
Totale	2.682

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	17	0	0	0	0	0	0	0	0	0	0	0	17
2021/2022	130	14	36	2	9	14	10	3	7	7	4	8	16
2022/2023	237	13	35	17	36	23	59	1	17	26	0	6	4
2023/2024	156	3	3	17	26	11	32	6	13	2	16	19	8
2024/2025	341	13	18	16	48	23	25	29	15	42	14	27	71
2025/2026	1.022	57	92	65	184	275	54	93	41	72	68	9	12
Totale													2.682

CATALOGO DEI PRODOTTI DELLA RICERCA